Jasna M. Jasna

Prof. Dr. Jasna M. Jasna


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2022 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
RGRichard Graham
Richard Graham
AMAna P. Moreira
Ana P. Moreira
Andor W. J. M. GlaudemansAndor W. J. M. Glaudemans
Andor W. J. M. Glaudemans
LJLars Thorbjørn Jenesn
Lars Thorbjørn Jenesn
JJJasna M. Jasna
Jasna M. Jasna
FJFrançois Jamar
François Jamar

15 July 2022 in Frontiers in Nuclear Medicine
Verified
Journal Article
Open access
JJJasna M. Jasna
Jasna M. Jasna
RKRonan P. Killeen
Ronan P. Killeen
Editorial: F-18 FDG PET/CT Imaging: Normal Variants, Pitfalls and Artifacts

7 May 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
JJJasna M. Jasna
Jasna M. Jasna
JRJelena Roganovic
Jelena Roganovic
ISIvana Starcevic
Ivana Starcevic
DNDr. Ivan Vladislav Nikolic
Dr. Ivan Vladislav Nikolic
NBNatasa Prvulovic Bunovic
Natasa Prvulovic Bunovic
ZNZoran Nikin
Zoran Nikin
Background/Objectives: Although the role of F-18 FDG PET/CT imaging is well established in oncology, its diagnostic value in routine monitoring for recurrent colorectal cancer (CRC) is still controversial. The aim was to evaluate the diagnostic value of FDG PET/CT in detecting recurrent CRC in correlation with CEA, CA 19-9 levels, and conventional imaging modalities (CIM). Methods: Between 2009 and 2023, we retrospectively studied 134 CRC patients referred for FDG PET/CT imaging on the suspicion of recurrence based on elevated CEA and/or CA 19-9, and/or equivocal radiological findings. According to the Institutional Tumor Board CRC protocol, after initial treatment which was dependent on TNM stage (neoadjuvant therapy, primary resection or adjuvant treatment), patients underwent a standard 5-year surveillance including CEA and CA 19-9 measurements, CIM, and colonoscopy every 6 months. The statistics including univariate and multivariable analyses were conducted using the IBM SPSS 20.0 statistical software. P-values <0.05 were considered statistically significant. Results: Recurrent CRC was confirmed in 54/134 (40.3%) patients with elevated tumor markers. FDG PET/CT shows high diagnostic performance in detecting recurrent CRC with sensitivity, specificity, PPV, NPV, and accuracy of 94.4%, 82.5%, 78.5%, 95.7%, and 87.3%, respectively. The CEA shows a high sensitivity of 98.1%, but both low specificity and accuracy of 15% and 48.5%, respectively. The sensitivity, specificity, and accuracy, for CA 19-9 and CIM for the correct diagnosis in CRC patients were: 44.4%, 67.5%, 58.2%, and 51.9%, 98.8%, 79.9%, respectively. The AUC for FDG PET/CT, elevated CEA levels, CIM, and elevated CA 19-9 levels was 0.885 (95% CI: 0.824-0.946; p<0.001), 0.844 (95% CI: 0.772-0.916; p<0.001), 0.753 (95% CI: 0.612-0.844; p<0.001); and 0.547 (95% CI: 0.442-0.652; p=0.358). Univariate analysis shows that both FDG PET/CT- and CIM-positive results were highly associated with CRC recurrence (p<0.001 and p<0.001, respectively), while gender, mucinous tumor type, presence of initial lymph node metastasis (N+), and presence of initial distant metastasis (M+) have no significance (p=0.211, p=0.158, p=0.583, and p=0.201, respectively). Our multivariate analysis shows that independent predictors for CRC recurrence are: positive FDG PET/CT scans (p<0.001), positive CIM results (p=0.001) and elevated CA19-9 levels (p=0.023). Although CA 19-9 was not detected as a statistically significant predictor in the univariate analysis (p=0.358), in a multivariate analysis it was recognized as a significant predicting factor in detecting CRC recurrence (p=0.023). Conclusions: FDG PET/CT shows a high diagnostic efficacy in CRC recurrence detection, in correlation with CEA levels, CA 19-9 levels, and CIM. This imaging modality should be routinely integrated into the postoperative follow-op in patients with elevated tumor markers.

9 January 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
JJJasna M. Jasna
Jasna M. Jasna
SNSladjana Novkovic-Ostojic
Sladjana Novkovic-Ostojic
ISIvana Starcevic
Ivana Starcevic
JRJelena Roganovic
Jelena Roganovic
MSMaja Stankov
Maja Stankov
MZMirjana Zivojinov
Mirjana Zivojinov
Clear cell renal cell carcinoma (ccRCC) represents the most common subtype of renal malignancy. Although nephrectomy remains the standard primary treatment, distant metastases may occur years after the initial diagnosis. Metastasis of ccRCC to the thyroid gland is an uncommon clinical event. We report a rare case involving concurrent metastatic ccRCC to the thyroid combined with a papillary thyroid carcinoma. A 61-year-old male with a prior history of metastatic ccRCC to the pancreas was referred to our institution for evaluation of thyroid enlargement. The patient underwent thyroid lobectomy, and histopathological analysis confirmed metastatic ccRCC within the thyroid tissue. Nine months postoperatively, routine ultrasound follow-up revealed a multinodular goiter in the contralateral thyroid lobe. Following completion thyroidectomy, histological examination identified a papillary thyroid carcinoma, staged as pT1a. Due to disease progression and recurrence of pancreatic metastasis, the patient was subsequently treated with tyrosine kinase inhibitor therapy. At the most recent follow-up, the patient remained alive and in good clinical condition. Given that ccRCC can metastasize many years after the initial diagnosis, prolonged follow-up is essential, particularly in patients presenting with thyroid nodules. Since metastatic lesions may mimic primary thyroid malignancies, accurate preoperative diagnosis, including fine-needle aspiration cytology and cell block with immunohistochemistry, is critical for guiding management. Total thyroidectomy remains the most effective treatment for isolated ccRCC metastasis to the thyroid gland.